UA131192U - METHOD OF FORECASTING OSTEOARTHrosis DEVELOPMENT - Google Patents

Abstract

A method for predicting the development of osteoarthritis includes clinical examination, radiography. Additionally in the patient's serum determine the polymorphism of the gene methylenetetrahydrofolate reductase (MTHFR C677T), the content of transforming growth factor beta 1 (TGF- (1), homocysteine, interleukin 6 (IL-6), C-reactive protein (SRP7). TT and TGF levels (1 <14 ng / ml, homocysteine> 20 μmol / l, IL-6> 10 ng / l, SRP> 6 mg / l predict osteoarthritis development.

Description

The proposed method of predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology, and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N. Okorokov. Diagnostics of diseases of internal organs. M., 2001. - vol. 2. - pp. 186-196).

The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications caused by the internal characteristics of the organism.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEV C677T), the content of transforming growth factor beta 1 (TGF-VDI1), homocysteine, interleukin 6 (IL-6), C- reactive protein (SRP) and homozygous carrier 677-TT, the content of TFR-VI "14 ng/ml, homocysteine 220 μmol/l, IL-6 210 ng/l, SRP "6 mg/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are performed, and the MTNEV C677T gene polymorphism is determined. The content is determined by the immunoenzymatic method

TFR-VI, homocysteine, IL-6, SRP. With homozygous carrier 677-TT, levels of TFR-VI1 "14 ng/ml, homocysteine 220 μmol/l, IL-6 "10 ng/l, SRP "6 mg/l predict the development of osteoarthritis.

A specific example of using the method.

Patient T., 58 years old, was hospitalized in the clinic due to pain syndrome in the left knee joint. X-rays were examined and performed. No signs of osteoarthritis were found. Polymorphism of MTNEV C677T gene was determined in blood serum. The content of TFR-B1, homocysteine, IL-6, PSA was determined by immunoenzymatic method. Homozygous carrier 677-TT was established.

Levels of TFR-B1-9.4 ng/ml, homocysteine - 33 μmol/l, IL-6-21 ng/l, SRP -17 mg/l. The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Zo

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that additionally in the patient's blood serum polymorphism of the methylenetetrahydrofolate reductase gene (MINEV C677T), the content of transforming growth factor beta 1 (TGF-RI), homocysteine, interleukin b (IL-6), C-reactive protein (CRP), and with homozygous carrier 677-111 and levels of TFR-RI1 "14 ng/ml, homocysteine 220 μmol/l, IL-b6 510 ng/l, SRP "6 mg/l predict the development of osteoarthritis.